PMID- 31132733
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200128
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 73
DP  - 2019 Aug
TI  - L-Fucose ameliorates DSS-induced acute colitis via inhibiting macrophage M1 
      polarization and inhibiting NLRP3 inflammasome and NF-kB activation.
PG  - 379-388
LID - S1567-5769(19)30534-X [pii]
LID - 10.1016/j.intimp.2019.05.013 [doi]
AB  - Previous studies reported that L-fucose had anti-inflammatory effects in 
      respiratory and cutaneous system. However, the effect of L-fucose on colitis and 
      the underlying mechanism is poorly understood. We studied the anti-inflammatory 
      effects of L-fucose on Dextran sulfate sodium (DSS)-induced acute colitis in vivo 
      and on LPS/ATP-induced bone marrow derived macrophages (BMDMs) damage in vitro. 
      Our results show that L-fucose significantly alleviated weight loss and disease 
      activity index (DAI) scores in colitis and reduced the infiltration of 
      macrophages and neutrophils. In addition, L-fucose can inhibit macrophage M1 
      polarization, inactivate the NLRP3 inflammasome and reduce the release of TNFalpha, 
      IL1beta, IL6 pro-inflammatory cytokines. In vitro studies showed that L-fucose 
      ameliorated cell damage resulting from the administration of LPS with ATP in 
      BMDMs, inhibited NLRP3 inflammasome activation and reduced the release of 
      corresponding pro-inflammatory cytokines. Finally, L-fucose can inhibit the 
      expression of p-NF-kB in vivo and in vitro. Overall, our results show that 
      L-fucose can attenuate colitis by inhibiting macrophage M1 polarization, 
      inhibiting NLRP3 inflammasome and NF-kB activation, and down-regulation of 
      pro-inflammatory cytokines.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - He, Ruohang
AU  - He R
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Li, Ying
AU  - Li Y
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Han, Chaoqun
AU  - Han C
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Lin, Rong
AU  - Lin R
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Qian, Wei
AU  - Qian W
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Hou, Xiaohua
AU  - Hou X
AD  - Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China. Electronic address: 
      houxh@medmail.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20190524
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cytokines)
RN  - 0 (Inflammasomes)
RN  - 0 (NF-kappa B)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Nlrp3 protein, mouse)
RN  - 28RYY2IV3F (Fucose)
RN  - 9042-14-2 (Dextran Sulfate)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Colitis/chemically induced/*drug therapy/immunology/pathology
MH  - Colon/drug effects/immunology/pathology
MH  - Cytokines/genetics/immunology
MH  - Dextran Sulfate
MH  - Fucose/pharmacology/*therapeutic use
MH  - Inflammasomes/immunology
MH  - Macrophages/drug effects/immunology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/immunology
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/immunology
OTO - NOTNLM
OT  - L-Fucose
OT  - NF-kB
OT  - NLRP3
OT  - Ulcerative colitis
EDAT- 2019/05/28 06:00
MHDA- 2020/01/29 06:00
CRDT- 2019/05/28 06:00
PHST- 2019/03/13 00:00 [received]
PHST- 2019/05/08 00:00 [revised]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2019/05/28 06:00 [entrez]
AID - S1567-5769(19)30534-X [pii]
AID - 10.1016/j.intimp.2019.05.013 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Aug;73:379-388. doi: 10.1016/j.intimp.2019.05.013. Epub 
      2019 May 24.